A non-coding single nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation
Author:
Yanchus Connor, Drucker Kristen L., Kollmeyer Thomas M., Tsai Ricky, Liang Minggao, Jiang Lingyan, Pawling Judy, Ali Asma, Decker Paul, Kosel Matt, Panda Arijit, Malik Ahmad, Al-Zahrani Khalid N., Hernandez J. Javier, Ahmed Musaddeque, Loganathan Sampath Kumar, Trcka Daniel, Michaelraj Antony, Fortin Jerome, Mazrooei Parisa, Zhou Lily, Elia Andrew, Lupien Mathieu, He Housheng Hansen, Wang Liguo, Abyzov AlexejORCID, Dennis James W., Wilson Michael D.ORCID, Wrana Jeffrey, Lachance Daniel, Wrensch Margaret, Wiencke John, Pennacchio Len A., Dickel Diane E., Visel Axel, Taylor Michael, Zadeh Gelareh, Dirks Peter, Eckel-Passow Jeanette E., Mak Tak, Kvon Evgeny, Jenkins Robert B., Schramek DanielORCID
Abstract
AbstractEstablishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single nucleotide polymorphism rs55705857 (A>G), which confers a 6-fold increased risk of IDH-mutant low-grade glioma (LGG) and is amongst the highest genetic associations with cancer. By fine-mapping the locus, we reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. To functionally test rs55705857, we generated an IDH1R132H-driven LGG mouse model and show that mutating the highly conserved, orthologous mouse rs55705857 locus dramatically accelerated tumor development from 463 to 172 days and increased penetrance from 30% to 75%. Overall, our work generates new LGG models and reveals mechanisms of the heritable predisposition to lethal glioma in ∼40% of LGG-patients.
Publisher
Cold Spring Harbor Laboratory
|
|